New combo aims to shrink lung tumors before surgery
NCT ID NCT04933903
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This phase 2 trial tests whether giving low-dose radiation along with two immunotherapy drugs (ipilimumab and nivolumab) before surgery can shrink tumors in people with stage IB to III non-small cell lung cancer. About 25 participants will receive the combination, then undergo surgery. The main goal is to see how many patients have a major or complete tumor response. The study also monitors safety and looks at immune markers in blood and tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rhode Island Hospital
RECRUITINGProvidence, Rhode Island, 02903, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab, Nivolumab, and low-dose stereotactic body radiation therapy
What this could lead to
If successful, this approach could improve tumor shrinkage before surgery, potentially leading to better outcomes for lung cancer patients.
What could go wrong
This is a small, early-phase study with only 25 participants, so results may not apply broadly. The combination of drugs and radiation carries risks of serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.